Max Healthcare Institute Limited (MAXHEALTH) — Financial Results | 21 November 2025

· NSE 🔴 High Importance ✨ Positive
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings

Max Healthcare reported 21% YoY revenue growth and 23% EBITDA growth in Q2 FY26, with H1 network gross revenue reaching ₹5,266 crores. The company commissioned 160 beds at Max Mohali and 268 beds at Nanavati-Max, with 400-bed Max Smart expected within 30 days. CGHS price revisions are projected to generate over ₹200 crores in additional revenue. Net profit grew 16% YoY, lagging EBITDA growth due to new hospital integrations and finance costs. Occupancy stood at 77% in Q2.

📄 View Original Announcement (PDF)

About Max Healthcare Institute Limited (MAXHEALTH)

Healthcare · Healthcare Services · Listed on NSE

Market Cap: ₹1,02,200.33 Cr P/E: 101.2

View full MAXHEALTH stock details →

📡 Get AI alerts when MAXHEALTH files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track MAXHEALTH — Free

📊 More MAXHEALTH filings

See all MAXHEALTH filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when MAXHEALTH files new disclosures

Track MAXHEALTH filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track MAXHEALTH — Free

Free account · 2 AI queries/day